Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
SPECIAL FEATURE - Injection Devices: Faster, Integrated, and Flexible for the IV to SC Transition
Contributor Cindy H. Dubin speaks with several companies who highlight how device developers are addressing various challenges while still ensuring precise dosage control and patient compliance.
WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine
Enabling technologies such as Nanotechnology, Amorphous Solid Dispersions, Self-emulsifying/nanoemulsifying drug delivery systems (SEDDS/SNEDDS) or Lipid Nano Particles (LNPs) for oral delivery are key elements for the development of complex and difficult to develop small molecules.
LIPID SOURCING & SELECTION - Navigating the Lipid Landscape: Overcoming the Challenges of Lipid Sourcing & Selection for LNPs
Donald Kelemen, PhD, says one of the most significant challenges lies in selecting and sourcing the molecules at the heart of LNPs: lipids. The right choices can optimize stability, efficacy, and scalability, while the wrong ones can introduce roadblocks that are difficult (and costly) to overcome.
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome
Artelo Biosciences, Inc. recently announced highly encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13,...Colorcon Ventures Invests in Phytolon to Advance the Future of Natural Colorants
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Phytolon, a startup company offering natural food coloring...Elicio Therapeutics Announces Positive Recommendation to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics, Inc. recently announced that following the Independent Data Monitoring Committee’s (IDMC) pre-specified interim review of the unblinded safety...Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety & Depression
Artelo Biosciences, Inc. recently announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency...etherna Achieves Major Milestones in its Bio-Reducible LNP Platform
etherna immunotherapies NV recently announced breakthrough innovation in efficient in vivo extrahepatic delivery of mRNA to several key tissues, including...WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice
OXYCAPT™ vial is the multilayer primary container with the distinctive structure that includes the gas barrier layer in the middle layer. They offer optimal features for the transport and storage of advanced therapeutics, such as cell and gene therapy products.
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Custome
CHASKA, Minn., Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed...
